Metacrine Announces Executive Leadership Changes
February 24 2022 - 4:05PM
Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical
company pioneering differentiated therapies for patients with
gastrointestinal diseases, today announced that Ms. Trisha Millican
has resigned her position as chief financial officer. Ms. Millican
will remain with the Company until March 31, 2022 to ensure a
smooth transition. In addition, Mr. Michael York, currently senior
vice president, business development and commercial strategy, has
been promoted to chief business officer. Mr. York will oversee all
business and corporate development activities for Metacrine
including evaluation and execution of licensing, partnering and
strategic transaction opportunities, as well as financial
operations.
“I want to recognize Trisha for her commitment and service to
Metacrine since our founding in 2015,” said Preston Klassen, M.D.,
MHS, CEO, Metacrine. “Trisha has been a dedicated leader and
collaborative partner to all of us and we wish her great success as
she moves on to future endeavors.”
Klassen continued, “Michael’s business development expertise,
extensive industry network and successful track record further
strengthens our corporate development effort. We look forward to
his contributions as we chart our path forward in 2022.”
About Metacrine
Metacrine, Inc. is a clinical-stage biopharmaceutical company
developing differentiated therapies to treat gastrointestinal
diseases. Metacrine has developed a proprietary farnesoid X
receptor (FXR) platform utilizing a unique chemical scaffold, which
has demonstrated an improved therapeutic profile in clinical
trials. To learn more, visit www.metacrine.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements in
this press release that are not purely historical are
forward-looking statements. Such forward-looking statements
include, among other things, statements about Ms. Millican’s
intentions to remain at Metacrine to facilitate the transition.
Words such as “may,” “will,” “expect,” “plan,” “aim,” “projected,”
“likely,” “anticipate,” “estimate,” “intend,” “potential,”
“prepare,” “perceived,” “believes” and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking
statements. These forward-looking statements are based on
Metacrine’s expectations and assumptions that may never materialize
or prove to be incorrect. Each of these forward-looking statements
involves risks and uncertainties. Actual results may differ
materially from those projected in any forward-looking statements
due to numerous risks and uncertainties. Information regarding
the foregoing and additional risks may be found in the section
entitled “Risk Factors” in Metacrine’s Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission (the “SEC”)
on November 12, 2021, and in Metacrine’s other filings with the
SEC. All forward-looking statements contained in this press release
speak only as of the date on which they were made. Except as
required by law, Metacrine assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
Investor & Media Contact
Investor Relations
Metacrine, Inc.
investors@metacrine.com
Metacrine (NASDAQ:MTCR)
Historical Stock Chart
From Sep 2024 to Oct 2024
Metacrine (NASDAQ:MTCR)
Historical Stock Chart
From Oct 2023 to Oct 2024